EAEric P. Anderson

Eric P. Anderson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric P. Anderson has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exposure–Response Relationships in Patients with Non‐Small‐Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3‐DXd)

    by Li Li, Mark Lee, Rujuta Joshi, Yuan Xu, Ramon Garcia, Kyle Baron, Eric Anderson, Tim Waterhouse, David Sternberg, Pomy Shrestha, et al.

    Patritumab deruxtecan (HER3‐DXd, also known as MK‐1022), an antibody‐drug conjugate consisting of a human epidermal growth factor receptor 3 (HER3) antibody attached to a topoisomerase I inhibitor payload (DXd), has demonstrated efficacy in patients with metastatic breast cancer and non‐small cell lung cancer (NSCLC). Exposure–efficacy was assessed in 446 patients with EGFR‐mutated NSCLC; exposure–safety was assessed in 715 patients with NSCLC, breast cancer, or colorectal cancer. A range of HER3‐DXd dosing regimens was evaluated, including fixed‐dosing regimens (1.6–8 mg/kg every 3 weeks [Q3W]; 3.2–6.4 mg/kg Q3W), an up‐titration dosing regimen, and an alternative Q2W/Q3W dosing regimen. Logistic regression or time‐to‐event models were used to test the relationships of each endpoint with pharmacokinetic analytes (anti‐HER3‐ac‐DXd and DXd). Anti‐HER3‐ac‐DXd exposure was positively associated with objective response rate, and bone metastasis was identified as a significant covariate. DXd exposure showed a stronger correlation with most safety endpoints compared with anti‐HER3‐ac‐DXd exposure, except for grade ≥ 2 nausea/vomiting and any grade adjudicated drug‐related interstitial lung disease (ILD). Dose response predictions verified a manageable safety profile for the 5.6 mg/kg Q3W regimen. This observation was supported by low predicted rates of adjudicated drug‐related ILD and adverse events leading to treatment discontinuation with the 5.6 mg/kg Q3W regimen. Overall, these results support the selection of HER3‐DXd 5.6 mg/kg Q3W as the recommended dosing regimen for patients with NSCLC, and these data inform the optimal dosing regimen for other tumor types.


  • Open Access

    gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve

    by Tong Lu, Victor Poon, Logan Brooks, Erick Velasquez, Eric Anderson, Kyle Baron, Jin Y. Jin, Matts Kågedal

    GPKPDviz is a Shiny application (app) dedicated to real‐time simulation, visualization, and assessment of the pharmacokinetic/pharmacodynamic (PK/PD) models. Within the app, gPKPDviz is capable of generating virtual populations and complex dosing and sampling scenarios, which, together with the streamlined workflow, is designed to efficiently assess the impact of covariates and dosing regimens on PK/PD end points. The actual population data from clinical trials can be loaded into the app for simulation if desired. The app‐generated dosing regimens include single or multiple dosing, and more complex regimens, such as loading doses or intermittent dosing. When necessary, the dosing regimens can be defined externally and loaded to the app for simulation. Using mrgsolve as the simulation engine, gPKPDviz is typically used for population simulation, however, with a slight modification of the mrgsolve model, gPKPDviz is capable of performing individual simulations with individual post hoc parameters, individual dosing logs, and individual sampling timepoints through an external dataset. A built‐in text editor has a debugging feature for the mrgsolve model, providing the same error messages as model compilation in R. GPKPDviz has had stringent validation by comparing simulation results between the app and using mrgsolve in R. GPKPDviz is a member of the suite of Modeling and Simulation Shiny apps developed at Genentech to facilitate the typical modeling work in Clinical Pharmacology. For broader access to the Pharmacometric community, gPKPDviz has been published as an open‐source application in GitHub under the terms of GNU General Public License.


  • Whole transcriptome analysis of smoker palatal mucosa identifies multiple downregulated innate immunity genes

    by Yun Wang, Eric P. Anderson, Dimitris N. Tatakis

    Background Smoking has significant negative impact on periodontal health and treatment outcomes. The molecular effects of smoking on oral immune homeostasis have not been fully elucidated. The present study aimed to provide a comprehensive assessment of smoking‐associated gene expression changes in healthy palatal mucosa and to identify potentially implicated immunologic pathways. Methods Palatal biopsies, in the form of connective tissue grafts, were obtained from periodontally healthy smokers and non‐smokers. Smoking status was biochemically verified (exhaled air CO and serum cotinine). Tissue samples were processed for next generation sequencing, quantitative real‐time PCR (qPCR), and immunohistochemistry. Gene set enrichment/pathway analysis and correlation analysis between gene expression and serum cotinine levels were also performed. Results Analysis of palatal tissues from 12 non‐smokers and 10 smokers identified 830 significantly(p2. Most increased in expression (≥5‐FC) were CYP1A1, CYP1B1, and USP17L9P; most decreased (≥6‐FC) were IL36A, DEFB4A, DEFB4B, SPRR2F, CCL20, KLK6, and ADH4. 203 DEGs (FC>2) were significantly correlated with serum cotinine levels. Significant enrichment pathways for cotinine‐associated genes include antimicrobial humoral response, regulation of humoral response and various metabolic processes. qPCR and immunohistochemistry confirmed gene and protein expression of selected DEGs. Conclusion Smoking has a significant effect on the transcriptome of normal human palatal mucosa and seems to target genes important for innate immune defenses, which may prove to be one of the key mechanisms by which tobacco smoking leads to increased periodontitis susceptibility. This article is protected by copyright. All rights reserved


  • Safety Performance of Flashing Yellow Arrow for Protected–Permissive Left-Turn Signal Control in Central Illinois

    by Kerrie L. Schattler, Eric P. Anderson, Trevor Hanson

    In 2010, the Illinois Department of Transportation began implementing the flashing yellow arrow (FYA) at intersections operating with protected–permissive left-turn (PPLT) control. Research was conducted to evaluate the safety-effectiveness of FYAs at 86 intersections and 164 approaches in central Illinois. The effectiveness evaluation was performed with 3 years of before-and-after FYA installation crash data and the empirical Bayes method. In the before condition, the left-turn signals operated with a circular green display indicating the permissive interval of PPLT control using a five-section signal head. In the after condition, the FYA replaced the circular green display for the permissive interval of PPLT with a four-section signal head. Supplemental traffic signs were mounted on the mast arm adjacent to the left-turn signal at over half of the FYA installations. The results of the comprehensive safety evaluation of the FYA for PPLT control are presented. Analyses were also performed to assess the effects of the FYA supplemental signs and the effects of the FYA overall on two subsets of at-fault drivers: older drivers (age 65+) and younger drivers (age 16 to 21). The resulting mean crash modification factors for the targeted crash types ranged from 0.589 to 0.714. The findings of this research support the continued use of FYAs for PPLT control to improve safety at signalized intersections in central Illinois.